# PUBLISHED VERSION

Kim Broekhuijsen, Josje Langenveld, Gert-Jan van Baaren, Mariëlle G van Pampus, Anton H van Kaam, Henk Groen, Martina Porath, Maureen TM Franssen, Ben W Mol, and HYPITAT-II study group
**Correction: Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia between 34 and 37 weeks' gestation (HYPITAT-II): a multicentre, open-label randomised controlled trial**
BMC Pregnancy and Childbirth, 2013; 13(1):232-1



Originally published at:
http://doi.org/10.1186/1471-2393-13-232

BMC Pregnancy & Childbirth

CORRECTION Open Access

# Correction: Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia between 34 and 37 weeks' gestation (HYPITAT-II): a multicentre, open-label randomised controlled trial

Kim Broekhuijsen[1*], Josje Langenveld[2], Gert-Jan van Baaren[3], Mariëlle G van Pampus[4], Anton H van Kaam[3], Henk Groen[5], Martina Porath[6], Maureen TM Franssen[1], Ben W Mol[3] and HYPITAT-II study group

The earliest draft versions of the protocol for our study described the composite adverse maternal outcome as one or more of progression to severe disease, pulmonary edema, thrombo-embolic disease, HELLP syndrome, eclampsia, placental abruption or maternal death. However, there is ongoing debate as to whether progression to severe disease should be considered an adverse maternal outcome [1,2]. Therefore, after obtaining funding which enabled us to increase our sample size to the current sample size of 680, we decided to study a composite adverse maternal outcome excluding progression to severe disease. These changes were incorporated in the protocol as submitted to and approved by the institutional review board;* the current protocol is available from our website (http://www.studies-obsgyn.nl/hypitat2/page.asp?page_id=642). Unfortunately, the change to the maternal outcome definition was not incorporated into the published protocol, which incorrectly includes progression to severe disease in the composite adverse maternal outcome [3].

We also discovered minor differences between the published protocol and the IRB approved protocol. The definition for neonatal morbidity should have contained meconium aspiration syndrome, pneumothorax and/or pneumomediastinum, periventricular leucomalacia, convulsions and other neurological abnormalities. Finally, low 5-minute Apgar score should have been defined as below 7 (as opposed to below 3), and low umbilical artery pH as below 7.05 (as opposed to below 7.0).

These discrepancies were discovered and the correction submitted for publication during recruitment.

* Medical Ethics Committee, Academic Medical Centre, Amsterdam, the Netherlands (ref. 2008/244).

**Author details**
[1]Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. [2]Department of Obstetrics and Gynecology, Atrium Medical Center, Heerlen, The Netherlands. [3]Department of Obstetrics and Gynecology, Academic Medical Center, Amsterdam, The Netherlands. [4]Department Obstetrics and Gynecology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands. [5]Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. [6]Department of Obstetrics and Gynecology, Maxima Medical Center, Veldhoven, The Netherlands.

Received: 24 January 2013 Accepted: 6 December 2013
Published: 23 December 2013

**References**

1. Koopmans CM, Bijlenga D, Groen H, Vijgen SM, Aarnoudse JG, Bekedam DJ, HYPITAT study group, *et al*: **Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial.** *Lancet* 2009, **374**:979–988.
2. Bewley S, Shennan A: **Hypitat and the fallacy of pregnancy interruption.** *Lancet* 2010, **375**(9709):119.
3. Langenveld J, Broekhuijsen K, van Baaren G, van Pampus MG, van Kaam AH, Groen H, Porath M, Mol BW, HYPITAT-II study group: **Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia between 34 and 37 weeks' gestation (HYPITAT-II): a multicentre, open-label randomised controlled trial.** *BMC Pregnancy Childbirth* 2011, **11**:50.

doi:10.1186/1471-2393-13-232
**Cite this article as:** Broekhuijsen *et al.*: Correction: Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia between 34 and 37 weeks' gestation (HYPITAT-II): a multicentre, open-label randomised controlled trial. *BMC Pregnancy and Childbirth* 2013 **13**:232.

* Correspondence: k.broekhuijsen@gmail.com
[1]Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Full list of author information is available at the end of the article